D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 72 Citations 22,353 289 World Ranking 14182 National Ranking 7507

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His primary areas of study are Internal medicine, Melanoma, Oncology, Cancer and Cancer research. His research integrates issues of Immune system, Immunotherapy, Biopsy and Drug resistance in his study of Melanoma. His Oncology research is multidisciplinary, relying on both Antibody, Dabrafenib and Neuroblastoma RAS viral oncogene homolog.

His research investigates the connection with Cancer and areas like Biomarker which intersect with concerns in Tumor-infiltrating lymphocytes and Carcinoma. His biological study spans a wide range of topics, including Anti pd 1, Toxicity and MAPK/ERK pathway. Douglas B. Johnson has researched Ipilimumab in several fields, including CTLA-4 and Nivolumab.

His most cited work include:

  • Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma (1334 citations)
  • Fulminant Myocarditis with Combination Immune Checkpoint Blockade (826 citations)
  • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (635 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Melanoma, Internal medicine, Cancer research, Oncology and Cancer. His studies deal with areas such as Immunology, Immune system, Immunotherapy, Targeted therapy and Neuroblastoma RAS viral oncogene homolog as well as Melanoma. In general Internal medicine study, his work on Ipilimumab, Adverse effect and Pembrolizumab often relates to the realm of In patient, thereby connecting several areas of interest.

His work carried out in the field of Ipilimumab brings together such families of science as Nivolumab, Clinical trial and Surgery. His research in Cancer research intersects with topics in Immune checkpoint, Trametinib, MAPK/ERK pathway and Mutation. His Cancer research includes themes of Bioinformatics, Intensive care medicine, Antibody, Biomarker and Fulminant.

He most often published in these fields:

  • Melanoma (45.72%)
  • Internal medicine (44.25%)
  • Cancer research (35.10%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (44.25%)
  • Melanoma (45.72%)
  • Cancer (22.42%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Internal medicine, Melanoma, Cancer, Adverse effect and Oncology. His research in the fields of Ipilimumab, Nivolumab and Retrospective cohort study overlaps with other disciplines such as In patient. His Melanoma study is concerned with the larger field of Cancer research.

Douglas B. Johnson combines subjects such as Fulminant, Disease, Immune system and Intensive care medicine with his study of Cancer. Douglas B. Johnson has included themes like Discontinuation, Myocarditis, Incidence, Pneumonitis and Immunotherapy in his Adverse effect study. His study looks at the relationship between Oncology and topics such as Clinical endpoint, which overlap with Trametinib, Cohort study and Cohort.

Between 2019 and 2021, his most popular works were:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
  • Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study (59 citations)
  • Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease (38 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His main research concerns Internal medicine, Adverse effect, Melanoma, Cancer and In patient. His Internal medicine research incorporates elements of Gastroenterology and Oncology. His Adverse effect research integrates issues from Body mass index and Myocarditis.

Melanoma is the subject of his research, which falls under Cancer research. His study in Cancer research is interdisciplinary in nature, drawing from both Targeted therapy, CDKN2A, Growth inhibition, Neuroblastoma RAS viral oncogene homolog and PTEN. His work deals with themes such as Quality of life, Blood pressure, Renal cell carcinoma, Lung cancer and Type 2 diabetes, which intersect with Cancer.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song.
Cell (2016)

1591 Citations

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias.
The New England Journal of Medicine (2016)

1052 Citations

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong.
Cancer Discovery (2014)

813 Citations

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka.
The New England Journal of Medicine (2017)

801 Citations

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra.
JAMA Oncology (2018)

667 Citations

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)

613 Citations

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson.
Annals of Oncology (2016)

505 Citations

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Willy Hugo;Hubing Shi;Lu Sun;Marco Piva.
Cell (2015)

467 Citations

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J. Moslehi;Joe Elie Salem;Jeffrey A. Sosman;Bénédicte Lebrun-Vignes.
The Lancet (2018)

430 Citations

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)

429 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Douglas B. Johnson

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 121

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 105

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 105

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 90

John F. Thompson

John F. Thompson

University of Sydney

Publications: 86

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 73

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 72

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 70

James Larkin

James Larkin

Royal Marsden NHS Foundation Trust

Publications: 70

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 65

Céleste Lebbé

Céleste Lebbé

Université Paris Cité

Publications: 63

Alexander M. Menzies

Alexander M. Menzies

University of Sydney

Publications: 63

Charles Swanton

Charles Swanton

The Francis Crick Institute

Publications: 61

Aurélien Marabelle

Aurélien Marabelle

Institut Gustave Roussy

Publications: 58

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 57

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 55

Something went wrong. Please try again later.